T. Koujitani et al., Tumor-promoting activity of 2,6-dimethylaniline in a two-stage nasal carcinogenesis model in N-bis (2-hydroxypropyl)nitrosamine-treated rats, CANCER LETT, 142(2), 1999, pp. 161-171
The potential promotion activity on nasal carcinogenesis of 2,6-dimethylani
line (DMA), an alpha(2)-adrenergic agonist metabolite of xylazine which is
used for food-producing animals as a sedative agent, was examined. Male F34
4 rats received diet containing 0 or 3000 ppm DMA for 52 weeks after initia
tion with N-bis(2-hydroxypropyl)nitrosamine (DHPN). Histopathological asses
sment showed the incidence of carcinomas in the DHPN+DMA group (33%) to be
significantly elevated as compared with that for the DHPN-alone group (5%).
Incidences and/or multiplicity of epithelial hyperplasias and dysplastic f
oci were also increased in the DHPN+DMA group. These lesions were exclusive
ly observed in the olfactory mucosa. The lowest plasma levels of DMA in tum
or- and dysplastic foci-bearing rats were 0.05 and 0.20 mu g/ml, respective
ly. These results indicate that DHPN acts as an appropriate initiator for n
asal carcinogenesis and that DMA exerts a tumor-promoting effect on the olf
actory mucosa in the rat nasal cavity. (C) 1999 Elsevier Science Ireland Lt
d. All rights reserved.